Triple combination therapy kills glioblastoma in mice by putting an “eat me” signal to the immune system on the surface of the brain tumor cells, blocking an offsetting “don’t eat me” signal and protecting a cancer-killing immune response launched by the combination.
The brain tumor treatment, as reported in Nature Communications, more than doubled median survival of mice treated with all three drugs, compared to those treated...
Researchers from MD Anderson have revealed how glioma cells move and infiltrate the brain, providing a new potential treatment pathway to...
Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the...
Glioblastoma is the most common, aggressive and deadly form of brain cancer. Median overall survival for primary glioblastoma is 14.6 months with the standard treatments of surgery, radiation therapy and the chemotherapy temozolomide, and falls to 5.5 – 11 months for recurrent glioblastoma.
Tumor heterogeneity and the blood-brain barrier make it difficult to treat glioblastoma. Immunotherapies such as immune checkpoint inhibitors...
A cold virus engineered to attack the most common and deadly of brain tumors allowed 20% of patients with recurrent glioblastoma to live for...
Patterns in how genes express themselves may help doctors personalize treatment for glioblastoma, the most deadly of brain cancers, according...
There are many moving parts when it comes to the mechanics of how otherwise healthy cells are transformed into those that cause deadly cancers...
When Allison Easley awoke one morning with soreness under her right armpit, she thought she’d pulled a muscle. But the pain soon became worse...
An international study has revealed new information about diffuse glioma, the most common type of tumor found in some 80% of adult brain cancer...
MD Anderson’s Moon Shots Program has expanded its targets, adding some of the most intractable cancers to its campaign to more rapidly convert...